Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Mineralys Therapeutics submitted a Form 144 reporting a proposed sale of 6,348 shares of common stock on 05/12/2026, tied to a broker-assisted cashless exercise of employee stock options. The filing lists a sequence of prior dispositions by David Rodman across February–May 2026, shown as individual sales (examples include 14,058 and 6,348 share lots).
Mineralys Therapeutics, Inc. reported a Form 144 notice for the proposed sale of 2,171 shares of common stock via a broker-assisted cashless exercise with an effective date of 05/11/2026. The filing lists multiple prior open-market dispositions by David Rodman in Feb–Apr 2026, including sales of 14,055 and 14,058 share blocks with corresponding dollar amounts shown in the record.
Mineralys Therapeutics, Inc. reported a Q1 2026 net loss of $39.3 million, slightly improved from $42.2 million a year earlier, as late‑stage trial spending declined. Research and development expenses fell to $24.4 million while general and administrative costs rose to $21.0 million as the company builds commercial capabilities.
The biopharmaceutical company is developing lorundrostat, an aldosterone synthase inhibitor for hypertension and related conditions. The FDA has accepted its New Drug Application and set a PDUFA target date of December 22, 2026. An exploratory Phase 2 sleep apnea trial missed its primary endpoint but showed meaningful blood pressure reductions.
Mineralys ended March 31, 2026 with $646.1 million in cash, cash equivalents, and investments and an accumulated deficit of $496.5 million. Operating cash outflow was $39.5 million in the quarter. The company also raised $20.2 million of net proceeds through its at‑the‑market equity program and had 82.5 million common shares outstanding.
Mineralys Therapeutics reported first quarter 2026 results and a major regulatory milestone for its lead drug, lorundrostat. The FDA accepted the New Drug Application for lorundrostat in adults with hypertension in combination with other drugs and set a PDUFA target date of December 22, 2026.
For the quarter ended March 31, 2026, net loss was $39.3 million, slightly improved from $42.2 million a year earlier, as research and development expenses fell to $24.4 million from $37.9 million after completion of the pivotal program. General and administrative expenses increased to $21.0 million from $6.6 million, reflecting higher professional fees and headcount. Cash, cash equivalents and investments totaled $646.1 million, and the company believes this will fund planned activities and operations into 2028.
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a small, pre-planned insider transaction. On April 17, 2026, he sold 416 shares of common stock in an open-market sale at $31.33 per share and exercised stock options for 416 shares at $15.44 per share. These trades were made under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following the sale, he directly owned 69,792 shares of common stock and held 4,584 stock options as reported in this filing.
Mineralys Therapeutics submitted a Form 144 notifying the sale of 416 shares of Common Stock on 04/17/2026 via a broker-assisted cashless exercise of employee stock options. The filing also lists multiple recent open-market dispositions by David Rodman over the prior three months, with individual sales such as 14,058 shares on 04/13/2026 ($373,086.81) and 6,348 shares on 04/15/2026 ($175,585.68).
Mineralys Therapeutics, Inc. Chief Medical Officer Rodman David Malcom reported option exercises and share sales in the company’s stock. On April 13, he exercised stock options covering a total of 14,058 shares of Common Stock at strike prices of $1.08, $10.20, and $14.25 per share. That same day, he conducted an open-market sale of 14,058 shares of Common Stock at a weighted-average price of $26.5391 per share. On April 15, he completed a second open-market sale of 6,348 shares at $27.66 per share under a Rule 10b5-1 trading plan. After these transactions, he directly holds 69,792 shares of Common Stock.
Mineralys Therapeutics, Inc. Chief Executive Officer Jon Congleton reported an open-market sale of 15,730 shares of common stock on April 13, 2026 at a weighted-average price of $26.8264 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Following this sale, Congleton directly holds 689,321 shares of Mineralys common stock, indicating that the transaction covers only a portion of his overall equity position. The shares were sold in multiple trades at prices ranging from $26.81 to $26.96.
David Rodman filed a Form 144 reporting proposed and recent sales of common stock. The notice lists a proposed sale of 6,348 shares tied to an exercise of employee stock options on 04/14/2025. The filing also records multiple completed sales between 01/09/2026 and 04/13/2026, including 14,058 shares sold on 04/13/2026 for $373,086.81.
Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options for 2,170 shares of common stock at $16.00 per share and then sold 2,170 shares in an open-market transaction at $27.38 per share.
These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. Following the sale, he directly holds 76,140 shares of Mineralys Therapeutics common stock.